Pfizer to Pull Exubera as Profits Plunge

  • Playlist
  • Download
  • Embed
    Embed <iframe src="http://www.npr.org/player/embed/15436580/15435869" width="100%" height="290" frameborder="0" scrolling="no">
  • Transcript

Pharmaceutical giant Pfizer plans to cancel its diabetes drug Exubera. The company expected the drug to become a blockbuster, but prescriptions are still less than 1 percent of the insulin market. That makes Exubera one of the most expensive miscalculations in the pharmaceutical industry's history. The failure will cost Pfizer $2.8 billion. It said overall profit plunged 72 percent.

Comments

 

Please keep your community civil. All comments must follow the NPR.org Community rules and terms of use, and will be moderated prior to posting. NPR reserves the right to use the comments we receive, in whole or in part, and to use the commenter's name and location, in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.